Table 1.

Selected ABC protein inhibitors evaluated in clinical trials.

Inhibitor	Target Protein	Clinical Trial Phase	State	Ref.
Valspodar (PSC 833, 5)	P-gp	III	Completed 1997–2000	[53]
Biricodar (VX-710, 7)	P-gp/MRP1	II	Terminated 1998–2001	[54]
Tariquidar (XR9576, 10)	P-gp	II	Completed 2003–2009	[55]
Zozuquidar (LY335979, 11)	P-gp	III	Completed 2002–2009	[56]
Elacridar (GF120918, 12)	BCRP	I	Completed 2002–2004	[57]
Dofequidar (MS-209, 13)	P-gp/MRP1	III	Completed	[40]
Sulindac (14)	MRP1	II	Completed 2008–2012	[58]
Tetrandrine/CBT1® (15)	P-gp	I	Ongoing. Start in March 2018	[59]
Erlotinib (16)	BCRP	I	Completed 2006–2009	[60]
Lapatinib (17)	BCRP	II	Completed 2007–2009	[61]